Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
21.01
-0.48 (-2.23%)
Apr 29, 2026, 9:51 AM EDT - Market open
Lyell Immunopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Revenue | 0.04 | 0.06 | 0.13 | 84.68 | 10.65 | Upgrade
|
| Revenue Growth (YoY) | -40.98% | -53.08% | -99.85% | 695.15% | 37.31% | Upgrade
|
| Gross Profit | 0.04 | 0.06 | 0.13 | 84.68 | 10.65 | Upgrade
|
| Selling, General & Admin | 45.14 | 52.04 | 66.98 | 117.31 | 89.06 | Upgrade
|
| Research & Development | 158.68 | 171.6 | 182.95 | 159.19 | 138.69 | Upgrade
|
| Other Operating Expenses | -5.49 | -4.65 | -4.3 | -4.86 | -3.53 | Upgrade
|
| Operating Expenses | 198.32 | 218.99 | 245.63 | 271.64 | 224.22 | Upgrade
|
| Operating Income | -198.29 | -218.93 | -245.5 | -186.96 | -213.57 | Upgrade
|
| Interest & Investment Income | 13.08 | 24.07 | 23.45 | 7.05 | 1.17 | Upgrade
|
| Other Non Operating Income (Expenses) | -19.83 | 0.89 | 1.85 | 1.89 | 0.1 | Upgrade
|
| EBT Excluding Unusual Items | -205.04 | -193.98 | -220.2 | -178.02 | -212.31 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -13 | -12.92 | -5 | -36.7 | Upgrade
|
| Gain (Loss) on Sale of Assets | -3.34 | -1.34 | -1.51 | -0.1 | -1.21 | Upgrade
|
| Asset Writedown | -1.44 | -51.3 | - | - | - | Upgrade
|
| Other Unusual Items | 1.71 | 3.8 | - | - | - | Upgrade
|
| Pretax Income | -274.45 | -342.99 | -234.63 | -183.12 | -250.22 | Upgrade
|
| Net Income | -274.45 | -342.99 | -234.63 | -183.12 | -250.22 | Upgrade
|
| Net Income to Common | -274.45 | -342.99 | -234.63 | -183.12 | -250.22 | Upgrade
|
| Shares Outstanding (Basic) | 17 | 13 | 13 | 12 | 7 | Upgrade
|
| Shares Outstanding (Diluted) | 17 | 13 | 13 | 12 | 7 | Upgrade
|
| Shares Change (YoY) | 30.74% | 4.18% | 1.58% | 81.79% | 925.18% | Upgrade
|
| EPS (Basic) | -16.06 | -26.23 | -18.70 | -14.82 | -36.82 | Upgrade
|
| EPS (Diluted) | -16.06 | -26.23 | -18.70 | -14.82 | -36.82 | Upgrade
|
| Free Cash Flow | -150.8 | -162.86 | -166.38 | -193.83 | -191.75 | Upgrade
|
| Free Cash Flow Per Share | -8.82 | -12.46 | -13.26 | -15.69 | -28.22 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -550791.67% | -358906.56% | -188845.39% | -220.77% | -2005.31% | Upgrade
|
| Profit Margin | -762355.56% | -562285.25% | -180486.15% | -216.24% | -2349.47% | Upgrade
|
| Free Cash Flow Margin | -418900.00% | -266980.33% | -127984.62% | -228.89% | -1800.50% | Upgrade
|
| EBITDA | -186.75 | -199.3 | -225.25 | -168.94 | -199.94 | Upgrade
|
| EBITDA Margin | - | - | - | -199.49% | - | Upgrade
|
| D&A For EBITDA | 11.54 | 19.63 | 20.25 | 18.02 | 13.62 | Upgrade
|
| EBIT | -198.29 | -218.93 | -245.5 | -186.96 | -213.57 | Upgrade
|
| EBIT Margin | - | - | - | -220.77% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.